Gapping up
In reaction to earnings/guidance:
- CASA +24.6%, AXTI +10.5%, AMN +9.2%, EVBG +7.8%, CMBM +6.2%, ANET +6.2%, AMAT +5.1%, DE +4.9%, GLOB +4.8%, MGA +4.7%, KIRK +4.7%, GVA +3.4%, FRO +3.3%, KNSL +3.1%, OLED +2.9% (also increases dividend), ADC +2.8%, LTC +2.6%, MMI +2.5%, OEC +2.4%, ROKU +2.2%, NWG +1.9%, KEYS +1.3%, POR +1.3%, COLD +1.1%
M&A news:
- RDFN +5% (to acquire RentPath for $608 mln in cash)
- KLR +4.9% (to acquire mobile messaging solution provider mGage for $215 mln and prices $200 mln of senior unsecured convertible notes and $125 mln common stock)
- SHW +0.6% (divests Wattyl Business)
Other news:
- DTIL +10.9% (announces 3-year pre-clinical study results showing long-term durability and safety of ARCUS in vivo gene editing to cut LDL cholesterol levels in nonhuman primates)
- NVAX +9.4% (announces MOU with Gavi for 1.1 bln doses of COVID-19 vaccine)
- IMCR +6.8% (receives FDA Breakthrough Therapy Designation for tebentafusp)
- RMO +5% (Romeo Power and Ecellix announce that they have entered into a Memorandum of Understanding to cooperate in the development, validation and launch of next-generation battery technology)
- NUS +4.6% (disclosed the purchase of ~21K shares worth more than $1 mln (transaction date 2/17))
- TVTX +4.5% (receives orphan designation for sparsentan)
- NGD +3.9% (provides operational outlook for New Afton Mine)
- NOVA +3% (secures capacity position in ISO-New England Forward Capacity Auction)
- SSYS +2.1% (acquires RP Support; slightly accretive to revenue and non-GAAP per-share earnings by the end of 2021)
- PEB +2% (successfully amended the agreements governing its outstanding debt, including its $650.0 million senior unsecured revolving credit facility)
- AGFY +1.7% (signs Letter of Intent for an additional $3 mln contract with Hannah Industries)
Analyst comments:
- EVBG +7.8% (upgraded to Overweight from Neutral at JP Morgan)
- NXGN +3.9% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- SABR +3% (upgraded to Buy from Hold at Deutsche Bank)
- CG +2.5% (upgraded to Outperform from Neutral at Credit Suisse)
- NMRK +2.4% (upgraded to Overweight from Neutral at Piper Sandler)
- HUBG +2.2% (upgraded to Buy from Neutral at UBS)
- KBH +2.2% (upgraded to Buy from Sell at Goldman)
- CDE +1.9% (upgraded to Buy from Neutral at ROTH Capital)
- FND +1.2% (upgraded to Overweight from Neutral at Piper Sandler)